CalBioreagents announces the release of 6 NEW Monoclonal Antibodies for MRSA.
MRSA are strains of Staphylococcus aureus that have developed resistance to beta lactam antibiotics. Resistance to these antibiotics is mediated by the MRSA MecA gene and the resulting mutant penicillin binding protein 2a (PBP2a). A series of monoclonal antibodies specific for the MRSA PBP2a protein have been developed by CalBioreagents’ partner company DINONA, Inc., (Korea).
These antibodies are available exclusively through CalBioreagents. The 6 PBP2a antibodies are suitable for the development of immunoassays to differentiate MRSA from Methicillin sensitive S. aureus.
CalBioreagents MRSA products include matched pairs of antibodies and a PBP2a recombinant protein.
For further information on our MRSA Monoclonals and other MRSA products, please visit the CalBioreagents website at www.calbioreagents.com or call at 916-630-1475.
